Gagan Singh, MD
Cardiovascular Disease · Sacramento, CANPI 1932356771
Payments from drug & device makers
Across 1,250 payments — averaging $1594.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$840K
- W. L. Gore & Associates, Inc.$362K
- Philips North America LLC$210K
- Edwards Lifesciences$203K
- Boston Scientific$141K
- Biosense Webster, Inc.$136K
- plus $101K from 16 others
What the payments were for
- Consulting fees$816,46667%
- Speaking & faculty fees$202,89217%
- Grants$2,6950%
- Travel & lodging$150,60712%
- Food & beverage$42,8934%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 660 | $840,188 |
| W. L. Gore & Associates, Inc. | 154 | $362,098 |
| Philips North America LLC | 118 | $209,937 |
| Edwards Lifesciences | 46 | $203,290 |
| Boston Scientific | 158 | $140,965 |
| Biosense Webster, Inc. | 4 | $135,847 |
| Baylis Medical Company Inc | 9 | $30,000 |
| Siemens Medical Solutions USA, Inc. | 28 | $28,358 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $18,914 |
| Renalpro Medical Inc. | 1 | $13,850 |
| Zimmer Biomet | 5 | $6,149 |
| Medtronic(2 entities) | 11 | $1,784 |
| Biotronik Inc. | 11 | $896 |
| Abiomed | 4 | $281 |
| Shockwave Medical, Inc | 10 | $176 |
| Cardiovascular Systems Inc. | 1 | $135 |
| Recor Medical Inc | 1 | $115 |
| Asahi Intecc USA, Inc. | 1 | $100 |
| Pfizer | 1 | $29 |
| Johnson & Johnson | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Cathworks, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Product in Development$264,009
- Mitra Clip system$153,664
- (9520) IGT Devices Undivided$135,891
- MitraClip$133,814
- GORE CARDIOFORM Septal Occluder$96,054
- WATCHMAN Access System$56,558
- MitraClip System$42,184
- VersaCross Access Solution$39,921
- (9148) ICE 3D$26,875
- NRG needle$20,625
- ACUSON SC2000 Diagnostic Ultrasound System$19,499
- LifeVest$18,443
- IGT Devices Und$15,680
- TRICLIP$15,419
- (9525) Intracardiac Und$9,210
- VersaCross$9,000
- IV Mid OEM$7,050
- WATCHMAN FLX$6,313
- Ultra ICE Plus$5,742
- ELCA$5,110
How this compares
$1,993,171 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 51 | $85,776 |
| EntrestoSacubitril/Valsartan | 29 | $39,963 |
| XareltoRivaroxaban | 22 | $20,831 |
| Repatha SureclickEvolocumab | 25 | $18,633 |
| JardianceEmpagliflozin | 13 | $14,013 |
| Atorvastatin Calcium | 77 | $1,304 |
| ClopidogrelClopidogrel Bisulfate | 73 | $1,192 |
| Metoprolol Succinate | 72 | $1,066 |
| Rosuvastatin Calcium | 27 | $684 |
| Carvedilol | 39 | $540 |
| Losartan Potassium | 34 | $455 |
| Amiodarone Hcl | 14 | $383 |
| Furosemide | 44 | $366 |
| Lisinopril | 25 | $317 |
| Amlodipine Besylate | 57 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $29 | $85,77651 claims |
| Johnson & JohnsonXarelto | $23 | $20,83122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Sacramento
- Jason RogersSacramento$5.1M
- Jeffrey SouthardSacramento$1.8M
- Thomas SmithSacramento$942K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Yu-Ping WangStanford$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.